An open-label, Multinational, Phase IIIb Study to Evaluate Patient and Satisfaction, Safety and Efficacy of Subcutaneous Administration of Trastuzumab in Patients With HER2-Positive Early Breast Cancer (ML28851) in Adjuvant/Neo-Adjuvant Setting

dc.authoridUslu, Ruchan/0000-0002-9584-6134
dc.authoridCicin, Irfan/0000-0002-7584-3868
dc.authoridMUSTAFA, ÖZGÜROĞLU/0000-0002-8417-8628
dc.authorwosidUslu, Ruchan/CAA-9946-2022
dc.authorwosidCicin, Irfan/AAQ-5575-2020
dc.authorwosidMUSTAFA, ÖZGÜROĞLU/A-8234-2016
dc.contributor.authorCicin, I.
dc.contributor.authorOukkal, M.
dc.contributor.authorMahfouf, H.
dc.contributor.authorMezlini, A.
dc.contributor.authorLarbaoui, B.
dc.contributor.authorSlim, B. A.
dc.contributor.authorUslu, R.
dc.date.accessioned2024-06-12T11:20:40Z
dc.date.available2024-06-12T11:20:40Z
dc.date.issued2018
dc.departmentTrakya Üniversitesien_US
dc.description11th European Breast Cancer Conference (EBCC) -- MAR 21-23, 2018 -- Barcelona, SPAINen_US
dc.description.abstract[Abstract Not Available]en_US
dc.identifier.doi10.1016/S0959-8049(18)30535-5
dc.identifier.endpageS103en_US
dc.identifier.issn0959-8049
dc.identifier.issn1879-0852
dc.identifier.startpageS102en_US
dc.identifier.urihttps://doi.org/10.1016/S0959-8049(18)30535-5
dc.identifier.urihttps://hdl.handle.net/20.500.14551/25714
dc.identifier.volume92en_US
dc.identifier.wosWOS:000429103100277en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherElsevier Sci Ltden_US
dc.relation.ispartofEuropean Journal Of Canceren_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subject[No Keywords]en_US
dc.titleAn open-label, Multinational, Phase IIIb Study to Evaluate Patient and Satisfaction, Safety and Efficacy of Subcutaneous Administration of Trastuzumab in Patients With HER2-Positive Early Breast Cancer (ML28851) in Adjuvant/Neo-Adjuvant Settingen_US
dc.typeConference Objecten_US

Dosyalar